CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts
New funding will expand CytoReason’s disease models and proprietary data, enabling R&D leaders at partner companies to make strategic decisions with greater speed and precision.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240717912688/en/
CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven, using computational disease models for predictive asset insights. Therapeutic area leaders, research teams, and scientists of all levels rely on CytoReason’s technology to increase the speed and accuracy of R&D decisions (Photo: Business Wire)
CytoReason will use this investment to expand the application of its models into additional indications, grow its proprietary molecular and clinical data, and establish an office in
Reduced R&D timelines and improved probability of technical and regulatory success (PTRS) are top priorities across life sciences companies. Speed, safety, and accuracy are critical when making asset-related R&D decisions. CytoReason provides therapeutic area leaders with molecular-level insights and valuable AI tools to make data-driven decisions, helping them improve the probability of phase 2 success and optimize their R&D portfolio.
Since the company announced the expansion of its
CytoReason’s technology and scientific breakthroughs are regularly published in top-tier journals such as Nature, Cell, and Gut. In 2023 alone, CytoReason’s scientists published 20 peer-reviewed articles in 16 journals, demonstrating the scientific throughput of the company’s team and technology.
Six of the world’s top ten pharma companies use CytoReason’s technology to make data-driven decisions in immunology, inflammation, immuno-oncology, metabolism, and other therapeutic areas.
CytoReason is excited to use this new funding to accelerate its growth and further cement its position in the market. This will enable more pharma and biotech companies to increase the speed and accuracy of asset development across therapeutic areas to benefit more patients worldwide.
Bank Hapoalim provided structured financing through its Tech Sector, Business Banking Division.
About CytoReason
CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven, using computational disease models for predictive asset insights. Therapeutic area leaders, research teams, and scientists of all levels rely on CytoReason’s technology to increase the speed and accuracy of R&D decisions. For example, scientists can prioritize potential targets and indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable insights by comparing their R&D portfolios to treatment alternatives. Learn more at www.cytoreason.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240717912688/en/
CytoReason Media Contact
zeev.benshachar@cytoreason.com
Source: CytoReason